BeOne Medicines (NASDAQ:ONC) Insider Titus Ball Sells 1,559 Shares of Company Stock

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) insider Titus Ball sold 1,559 shares of BeOne Medicines stock in a transaction that occurred on Friday, November 6th. The stock was sold at an average price of $405.57, for a total transaction of $632,283.63. Following the completion of the sale, the insider owned 880 shares of the company’s stock, valued at $356,901.60. This trade represents a 63.92% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website.

BeOne Medicines Price Performance

NASDAQ ONC opened at $424.00 on Wednesday. The company has a debt-to-equity ratio of 0.14, a current ratio of 3.55 and a quick ratio of 3.19. The stock’s fifty day moving average price is $365.79 and its 200 day moving average price is $327.15. BeOne Medicines Ltd. – Sponsored ADR has a 1 year low of $253.95 and a 1 year high of $424.73. The company has a market cap of $46.55 billion, a price-to-earnings ratio of 50.71 and a beta of 0.63.

BeOne Medicines (NASDAQ:ONC) last released its quarterly earnings data on Thursday, November 5th. The company reported $3.64 EPS for the quarter, beating the consensus estimate of $2.34 by $1.30. The business had revenue of $1.89 billion for the quarter, compared to the consensus estimate of $1.76 billion. BeOne Medicines had a net margin of 13.86% and a return on equity of 19.04%. As a group, equities research analysts forecast that BeOne Medicines Ltd. – Sponsored ADR will post 8.99 earnings per share for the current year.

Hedge Funds Weigh In On BeOne Medicines

Hedge funds have recently bought and sold shares of the business. Bank of America Corp DE grew its holdings in BeOne Medicines by 7.0% in the first quarter. Bank of America Corp DE now owns 405,273 shares of the company’s stock valued at $120,354,000 after purchasing an additional 26,441 shares during the period. Baird Financial Group Inc. raised its stake in shares of BeOne Medicines by 5.5% during the 2nd quarter. Baird Financial Group Inc. now owns 368,978 shares of the company’s stock worth $105,148,000 after buying an additional 19,327 shares during the period. First Trust Advisors LP raised its stake in shares of BeOne Medicines by 91.9% during the 1st quarter. First Trust Advisors LP now owns 241,426 shares of the company’s stock worth $71,696,000 after buying an additional 115,601 shares during the period. Jennison Associates LLC raised its stake in shares of BeOne Medicines by 102.1% during the 1st quarter. Jennison Associates LLC now owns 154,465 shares of the company’s stock worth $45,871,000 after buying an additional 78,027 shares during the period. Finally, Arrowstreet Capital Limited Partnership lifted its position in shares of BeOne Medicines by 96.3% during the 1st quarter. Arrowstreet Capital Limited Partnership now owns 110,586 shares of the company’s stock valued at $32,841,000 after buying an additional 54,260 shares in the last quarter. Hedge funds and other institutional investors own 48.55% of the company’s stock.

Analysts Set New Price Targets

ONC has been the subject of several recent research reports. Wolfe Research reaffirmed an “outperform” rating and set a $370.00 target price on shares of BeOne Medicines in a report on Monday, August 10th. TD Cowen boosted their target price on shares of BeOne Medicines from $424.00 to $454.00 and gave the company a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings raised shares of BeOne Medicines from a “hold (c+)” rating to a “buy (b-)” rating in a report on Thursday, October 8th. Royal Bank Of Canada raised their price target on shares of BeOne Medicines from $459.00 to $465.00 and gave the company an “outperform” rating in a research report on Friday, November 6th. Finally, JPMorgan Chase & Co. raised their price target on shares of BeOne Medicines from $425.00 to $445.00 and gave the company an “overweight” rating in a research report on Thursday, October 1st. One investment analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Hold rating to the company. According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus price target of $436.92.

About BeOne Medicines

BeOne Medicines, formerly known as BeiGene, is a global biotechnology company focused on discovering, developing, manufacturing and commercializing cancer medicines. Founded in Beijing in 2010, the company has expanded its research and commercial operations across multiple regions, including the United States, Europe and Asia. Its marketed products include Brukinsa (zanubrutinib), a targeted therapy for certain blood cancers, and Tevimbra (tislelizumab), an immunotherapy used to treat several types of cancer.